The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NBIX | +13.73% | +37.43% | +6.56% | +937% |
| S&P | +17.45% | +75.43% | +11.88% | +897% |
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $805.50M | 28.3% |
| Gross Profit | $787.90M | 28.7% |
| Gross Margin | 97.82% | 0.3% |
| Market Cap | $14.14B | 2.3% |
| Market Cap / Employee | $7.07M | 0.0% |
| Employees | 2K | 11.1% |
| Net Income | $153.70M | 49.1% |
| EBITDA | $235.40M | 54.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $713.00M | 206.0% |
| Accounts Receivable | $686.80M | 43.4% |
| Inventory | 69 | 20.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $415.30M | -8.7% |
| Short Term Debt | $56.00M | 37.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 11.13% | 1.6% |
| Return On Invested Capital | 12.25% | 1.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $390.80M | 66.2% |
| Operating Free Cash Flow | $388.40M | 60.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 37.50 | 37.10 | 33.53 | 30.39 | -26.74% |
| Price to Book | 4.25 | 4.91 | 5.16 | 4.71 | -7.34% |
| Price to Sales | 4.70 | 5.06 | 5.36 | 5.14 | -13.78% |
| Price to Tangible Book Value | 4.31 | 4.98 | 5.23 | 4.76 | -7.62% |
| Price to Free Cash Flow TTM | 23.03 | 24.01 | 24.26 | 19.64 | -22.07% |
| Enterprise Value to EBITDA | 347.80 | 79.85 | 55.68 | 58.19 | -34.27% |
| Free Cash Flow Yield | 4.3% | 4.2% | 4.1% | 5.1% | 28.32% |
| Return on Equity | 12.4% | 13.4% | 15.0% | 16.4% | 15.72% |
| Total Debt | $493.10M | $489.80M | $479.70M | $471.30M | -4.92% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
